Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H J Lüddeke

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Deutsche Medizinische Wochenschrift (1946)|May 3, 2002
[Do we need new ways of cell and gene treatment of diabetics? - Contra]H J Lüddeke
International Journal of Clinical Practice. Supplement|April 3, 2003
Postprandial hyperglycaemia--its importance and implicationsH J Lüddeke
Fortschritte Der Medizin|January 16, 1999
[Continuing education provided by the Diabetes Society. Results of the UKPDS (United Kingdom Diabetes Society) and therapeutic guidelines concerning diabetes type II]H J Lüddeke
International Journal of Clinical Practice. Supplement|November 7, 2000
Improving post-prandial control with Humalog and Humalog mixturesH J Lüddeke
Der Internist|March 1, 1990
[Possibilities and risks of insulin pump therapy]R Renner, H J Lüddeke
MMW Fortschritte Der Medizin|June 29, 2000
[Insulin resistance. Frequently administration errors are the source]T Rendschmidt, H J Lüddeke, R Renner, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyL F Meneghini, K H Rosenberg, C Koenen, et al.
Diabetes, Obesity & Metabolism|November 24, 2007
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVEA Dornhorst, H-J Lüddeke, C Koenen, et al.
International Journal of Clinical Practice|March 8, 2008
Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE studyA Dornhorst, H-J Lüddeke, S Sreenan, et al.
International Journal of Clinical Practice|February 23, 2007
Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohortA Dornhorst, H-J Lüddeke, S Sreenan, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Deutsche Medizinische Wochenschrift (1946)|May 3, 2002
[Do we need new ways of cell and gene treatment of diabetics? - Contra]H J Lüddeke
International Journal of Clinical Practice. Supplement|April 3, 2003
Postprandial hyperglycaemia--its importance and implicationsH J Lüddeke
Fortschritte Der Medizin|January 16, 1999
[Continuing education provided by the Diabetes Society. Results of the UKPDS (United Kingdom Diabetes Society) and therapeutic guidelines concerning diabetes type II]H J Lüddeke
International Journal of Clinical Practice. Supplement|November 7, 2000
Improving post-prandial control with Humalog and Humalog mixturesH J Lüddeke
Der Internist|March 1, 1990
[Possibilities and risks of insulin pump therapy]R Renner, H J Lüddeke
MMW Fortschritte Der Medizin|June 29, 2000
[Insulin resistance. Frequently administration errors are the source]T Rendschmidt, H J Lüddeke, R Renner, et al.
Diabetes, Obesity & Metabolism|March 30, 2007
Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyL F Meneghini, K H Rosenberg, C Koenen, et al.
Diabetes, Obesity & Metabolism|November 24, 2007
Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVEA Dornhorst, H-J Lüddeke, C Koenen, et al.
International Journal of Clinical Practice|March 8, 2008
Insulin detemir improves glycaemic control without weight gain in insulin-naïve patients with type 2 diabetes: subgroup analysis from the PREDICTIVE studyA Dornhorst, H-J Lüddeke, S Sreenan, et al.
International Journal of Clinical Practice|February 23, 2007
Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE European cohortA Dornhorst, H-J Lüddeke, S Sreenan, et al.
Pageof 2